Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma

Anthony Bejjani; Richard S Finn

doi:10.1016/j.soc.2023.06.003

Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma

Surg Oncol Clin N Am. 2024 Jan;33(1):73-85. doi: 10.1016/j.soc.2023.06.003. Epub 2023 Aug 12.

Authors

Anthony Bejjani¹, Richard S Finn²

Affiliations

¹ Hematology/Oncology, VA Greater Los Angeles Health System, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA.
² Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine at UCLA, 2825 Santa Monica Boulevard, Suite 200, Santa Monica, CA 90404, USA. Electronic address: rfinn@mednet.ucla.edu.

PMID: 37945146
DOI: 10.1016/j.soc.2023.06.003

Abstract

The recognition that hepatocellular carcinoma (HCC) is a rising problem globally dates back decades; however, the development of effective medical treatment for the disease has only led to robust improvements in patient outcomes in the recent past. As knowledge evolves and regimens are proven to be more active, the importance of multidisciplinary management in patients with all stages of HCC will become more important to optimize patient outcomes. Key to optimizing patient outcomes is an understanding of the evolution and current role of these therapies in the HCC landscape.

Keywords: HCC; Hepatocellular carcinoma; Immunotherapy; Systemic therapy; Treatment.

Publication types

Review

MeSH terms

Antineoplastic Agents* / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / pathology
Humans
Immunotherapy
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology
Treatment Outcome

Substances

Antineoplastic Agents